Protein Misfolding and Aggregation: The Relatedness between Parkinson's Disease and Hepatic Endoplasmic Reticulum Storage Disorders

Int J Mol Sci. 2021 Nov 18;22(22):12467. doi: 10.3390/ijms222212467.

Abstract

Dysfunction of cellular homeostasis can lead to misfolding of proteins thus acquiring conformations prone to polymerization into pathological aggregates. This process is associated with several disorders, including neurodegenerative diseases, such as Parkinson's disease (PD), and endoplasmic reticulum storage disorders (ERSDs), like alpha-1-antitrypsin deficiency (AATD) and hereditary hypofibrinogenemia with hepatic storage (HHHS). Given the shared pathophysiological mechanisms involved in such conditions, it is necessary to deepen our understanding of the basic principles of misfolding and aggregation akin to these diseases which, although heterogeneous in symptomatology, present similarities that could lead to potential mutual treatments. Here, we review: (i) the pathological bases leading to misfolding and aggregation of proteins involved in PD, AATD, and HHHS: alpha-synuclein, alpha-1-antitrypsin, and fibrinogen, respectively, (ii) the evidence linking each protein aggregation to the stress mechanisms occurring in the endoplasmic reticulum (ER) of each pathology, (iii) a comparison of the mechanisms related to dysfunction of proteostasis and regulation of homeostasis between the diseases (such as the unfolded protein response and/or autophagy), (iv) and clinical perspectives regarding possible common treatments focused on improving the defensive responses to protein aggregation for diseases as different as PD, and ERSDs.

Keywords: Parkinson’s disease; alpha-1-antitrypsin; alpha-1-antitrypsin deficiency; alpha-synuclein; endoplasmic reticulum storage disease; fibrinogen; hereditary hypofibrinogenemia with hepatic storage; protein aggregation; protein misfolding.

Publication types

  • Review

MeSH terms

  • Afibrinogenemia / drug therapy
  • Afibrinogenemia / genetics*
  • Afibrinogenemia / metabolism
  • Afibrinogenemia / pathology
  • Animals
  • Autophagy / drug effects
  • Autophagy / genetics
  • Coagulants / therapeutic use
  • Endoplasmic Reticulum / drug effects
  • Endoplasmic Reticulum / metabolism
  • Endoplasmic Reticulum / pathology
  • Fibrinogen / chemistry*
  • Fibrinogen / genetics
  • Fibrinogen / metabolism
  • Gene Expression Regulation
  • Humans
  • Liver / metabolism
  • Liver / pathology
  • Neuroprotective Agents / therapeutic use
  • Parkinson Disease / drug therapy
  • Parkinson Disease / genetics*
  • Parkinson Disease / metabolism
  • Parkinson Disease / pathology
  • Protease Inhibitors / therapeutic use
  • Protein Aggregates / drug effects
  • Protein Folding / drug effects
  • Unfolded Protein Response / drug effects
  • alpha 1-Antitrypsin / chemistry*
  • alpha 1-Antitrypsin / genetics
  • alpha 1-Antitrypsin / metabolism
  • alpha 1-Antitrypsin Deficiency / drug therapy
  • alpha 1-Antitrypsin Deficiency / genetics*
  • alpha 1-Antitrypsin Deficiency / metabolism
  • alpha 1-Antitrypsin Deficiency / pathology
  • alpha-Synuclein / chemistry*
  • alpha-Synuclein / genetics
  • alpha-Synuclein / metabolism

Substances

  • Coagulants
  • Neuroprotective Agents
  • Protease Inhibitors
  • Protein Aggregates
  • SERPINA1 protein, human
  • SNCA protein, human
  • alpha 1-Antitrypsin
  • alpha-Synuclein
  • Fibrinogen